Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Proteasome Activity
100%
Peptidase
100%
Multi-target
100%
Chymotrypsin
100%
Potential Therapeutic Strategies
100%
Malignant Astrocytoma
100%
Small Molecules
30%
Stem Cells
30%
Glioma
30%
Temozolomide
30%
Apoptosis
30%
Astrocytoma
30%
Patient-derived
30%
Blood-brain Barrier
20%
Standard of Care
20%
Established Cell Lines
20%
Dual Inhibition
20%
Reactive Oxygen Species Generation
20%
Novel Therapeutics
10%
Tumor
10%
Hypoxia
10%
Loss Function
10%
Antitumor Activity
10%
Genetic Model
10%
Overexpression
10%
Apoptosis Induction
10%
Chemotherapy
10%
Murine Model
10%
Mitochondrial Metabolism
10%
Proteasome Inhibition
10%
Invasiveness
10%
Drug Resistance
10%
Clinical Translational
10%
Primary Brain Tumor
10%
Stemness
10%
Therapeutic Efficacy
10%
Patient Survival
10%
Translational Studies
10%
Protease Inhibitors
10%
Drug Sensitivity
10%
Respiration
10%
Overall Survival
10%
Reactive Oxygen Species
10%
Malignant Phenotype
10%
Isocitrate Dehydrogenase 1 (IDH1)
10%
Tumor Site
10%
Tumor Recurrence
10%
Selective Activity
10%
Orthotopic Xenograft
10%
Poor Clinical Outcomes
10%
Astrocytoma Cells
10%
Dual Inhibitor
10%
Protein Processing
10%
Orthotopic Glioma
10%
Protein Adaptation
10%
Novel Treatments
10%
Mitochondria-dependent
10%
Structure-activity Modeling
10%
Adaptation to Hypoxia
10%
Abnormal Protein
10%
Medicine and Dentistry
Oligoastrocytoma
100%
Proteasome
100%
Chymotrypsin
100%
Peptidase
100%
Programmed Cell Death
40%
Temozolomide
30%
Reactive Oxygen Species
30%
Hypoxia
20%
Ganglioglioma
20%
Blood Brain Barrier
20%
Glioma Stem Cell
20%
Cell Line
20%
Biological Marker
10%
In Vitro
10%
Neoplasm
10%
Xenograft
10%
Mitochondrion
10%
Recurrent Disease
10%
Protein Processing
10%
Proteasome Inhibitor
10%
Drug Sensitivity
10%
Overall Survival
10%
Tumor Recurrence
10%
Antineoplastic Activity
10%
Mitochondrial Respiration
10%
Intracranial Tumor
10%
Tumor
10%
Drug Resistance
10%
Isocitrate Dehydrogenase
10%
Chemotherapy
10%
Astrocytoma Cell Line
10%
Genetics
10%
Neuroscience
Astrocytoma
100%
Proteasome
100%
Chymotrypsin
100%
Peptidase
100%
Glioma
36%
Programmed Cell Death
36%
Reactive Oxygen Species
27%
Cell Line
27%
Temozolomide
27%
Stem Cell
18%
Blood Brain Barrier
18%
Chemotherapy
9%
Mitochondrion
9%
Isocitrate Dehydrogenase
9%
In Vitro
9%
Mitochondrial Respiration
9%
Posttranslational Modification
9%
Drug Resistance
9%
Proteasome Inhibitor
9%
Intracranial Tumor
9%
Biological Marker
9%
Genetics
9%
Drug Sensitivity
9%
Pharmacology, Toxicology and Pharmaceutical Science
Astrocytoma
100%
Proteasome
100%
Peptidase
100%
Chymotrypsin
100%
Glioma
36%
Temozolomide
27%
Reactive Oxygen Metabolite
27%
Hypoxia
18%
Neoplasm
18%
Blood-Brain Barrier
18%
Preclinical Study
9%
Biological Marker
9%
Chemotherapy Regimens
9%
Recurrent Disease
9%
Overall Survival
9%
Tumor Recurrence
9%
Intracranial Tumor
9%
Proteasome Inhibitor
9%
Drug Resistance
9%
Isocitrate Dehydrogenase
9%